Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Study To Evaluate The Safety, Tolerability, Pharmacokinetic Profile And Preliminary Efficacy Of Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Next Previous
Trial Profile

A Phase Ib/II Study To Evaluate The Safety, Tolerability, Pharmacokinetic Profile And Preliminary Efficacy Of Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fruquintinib (Primary) ; Sintilimab (Primary)
  • Indications Adenocarcinoma; Carcinoma; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Liver cancer; Malignant thymoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Acronyms FRUSICA-1
  • Sponsors Hutchison MediPharma; HUTCHMED

Most Recent Events

  • 23 May 2025 According to HUTCHMED media release, the data of this trial will be presented at the American Society of Clinical Oncology Annual Meeting
  • 06 Apr 2025 Status changed from active, no longer recruiting to completed.
  • 18 Mar 2025 According to an Innovent Biologics media release, results from this study published in Targeted Oncology in January 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top